Floatz logo

Irinotecan

Radiation Maculopathy

Arman MashayekhiSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Radiation Maculopathy cohort.

Asset / SponsorPhaseRating
immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 1-chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain
Shields, Shields and Associates
Phase 4BB
(+)-VINCRISTINE
Arman Mashayekhi
Phase 2CCC
Ozurdex
Arman Mashayekhi
Phase 2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →